0001193125-26-076793 | 10-K | XBRL Viewer

Net Loss Per Share - Summary of Diluted Net Loss Per Share Attributable to Common Stockholders (Detail) - shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	2,213,601	1,652,453
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	1,951,417	1,626,841
Unvested Restricted Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	262,184	25,612

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

Basis of Presentation

The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”). Any reference in these notes to applicable guidance refers to U.S. GAAP as codified in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”).

Principles of Consolidation

The Company consolidates the financial statements of its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Reverse Stock Split and Exchange Ratio

Upon the closing of the Merger, each outstanding share of Legacy Tectonic’s common stock, including outstanding and unvested restricted stock, was converted into the right to receive a number of shares of AVROBIO’s common stock based on the Exchange Ratio of 0.53, after giving effect to the 1-for-12 reverse stock split of AVROBIO common stock that was effected on June 20, 2024. The exchange ratio was retroactively applied to all outstanding common shares, convertible preferred shares, stock options and restricted stock for all periods presented.

Use of Estimates

The preparation of the Company’s consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. These estimates are based on historical experience and other assumptions that the Company believes are reasonable under the circumstances. Revisions to estimates are recorded in the period in which the change becomes known.

Significant estimates include the valuation of stock-based awards, prepaid and accrued research and development activities, and income taxes. Actual results may differ from these estimates, and such differences could be material to the Company’s financial position and results of operations.

Foreign Currency

The operations of each of the Company’s subsidiaries are measured in the currency of the primary economic environment in which the subsidiary operates (the “functional currency”). Assets and liabilities of foreign subsidiaries whose functional currency is the local currency are translated into U.S. dollars using period-end exchange rates. Income and expense items are translated at the average exchange rate in effect during each fiscal month. Translation adjustments resulting from the remeasurement of foreign subsidiary financial statements are included as a component of Accumulated Other Comprehensive Loss in the Consolidated Balance Sheets. Gains and losses from foreign currency transactions are included in Other Income (Expense), Net in the Consolidated Statements of Operations and Comprehensive Loss.

Segment Information

Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The Company’s CODM is its chief executive officer, who reviews financial information on a consolidated basis for the purpose of making operating decisions, assessing financial performance, and allocating resources. The Company manages and evaluates its operations on a consolidated basis and has one reportable segment. The CODM primarily evaluates the Company’s performance based on net loss and reviews significant expense categories at the consolidated level. Segment assets are not separately monitored, as the CODM focuses on cash and expense impact. Refer to Note 16, Segment Information, for additional disclosures regarding the Company’s single reportable segment, including segment net loss and significant expense categories.

Summary of Significant Accounting Policies

Cash, Cash Equivalents, Restricted Cash, and Concentration of Credit Risk

The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. Cash and cash equivalents consisted of cash on deposit with banks denominated in U.S. dollars and investments in money market funds.

Restricted cash represents cash held to support letters of credit related to certain operating leases and is classified within other current or non-current assets on the Consolidated Balance Sheets based on the expected timing of release.

The following table provides a reconciliation of cash, cash equivalents and restricted cash within the Consolidated Balance Sheets that total the same such amounts shown in the Consolidated Statements of Cash Flows:


	December 31,
	2025		2024
Cash and cash equivalents	$	253,798	$	141,239
Restricted cash		1,072		587
Cash, cash equivalents and restricted cash		254,870		141,826

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and restricted cash. The Company maintains its cash, cash equivalents, and restricted cash with multiple accredited financial institutions. Deposits held with these institutions may exceed federally insured limits. The Company has not experienced any losses related to these accounts and does not believe it is exposed to significant credit risk beyond the normal risks associated with commercial banking relationships.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, generally ranging from three to five years, depending on the nature of the asset. Leasehold improvements are amortized over the shorter of the asset’s estimated useful life or the remaining lease term.

Construction-in-progress reflects amounts incurred for property and equipment that have not yet been placed in service and, accordingly, are not depreciated or amortized until the related assets are ready for their intended use.

Expenditures for major renewals and improvements that extend the useful life of an asset or increase its functionality are capitalized when they meet the Company’s capitalization criteria. Routine maintenance and minor repairs that do not extend the useful life of an asset are expensed as incurred.

Upon retirement or disposal of property and equipment, the cost of the asset and the related accumulated depreciation are removed from the accounts, and any resulting gain or loss is included in operating expenses in the Consolidated Statements of Operations and Comprehensive Loss.

Long-Lived Assets

The Company reviews long-lived assets, which consist primarily of property and equipment, for impairment in accordance with ASC 360, Property, Plant, and Equipment. Long-lived assets are evaluated for recoverability whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. Asset groups are determined at the lowest level for which identifiable cash flows are largely independent.

Recoverability is assessed by comparing the carrying amount of the asset group to the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset group. If the carrying amount exceeds the undiscounted cash flows, an impairment loss is recognized and measured as the amount by which the carrying amount exceeds the asset group’s fair value. Fair value is determined using valuation techniques consistent with ASC 820, Fair Value Measurement, which may include market and income approaches, as appropriate.

Changes in estimates of useful lives or residual values are accounted for prospectively and result in adjustments to depreciation or amortization expense over the remaining useful lives of the related assets.

No impairment losses were recognized during the years ended December 31, 2025 and 2024.

Fair Value Measurements

The Company measures certain financial instruments at fair value on a recurring basis. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Fair value is a market-based measurement and is determined based on assumptions that market participants would use in pricing an asset or liability.

The Company’s financial instruments measured at fair value consist solely of cash equivalents, which are valued using quoted prices in active markets. Accordingly, these instruments are classified within Level 1 of the fair value hierarchy. The Company does not have any financial instruments classified within Level 2 or Level 3 of the fair value hierarchy.

A three-level fair value hierarchy has been established to prioritize the inputs used in measuring fair value as follows:

Level 1 — Quoted prices in active markets for identical assets or liabilities.

Level 2 — Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or valuations with significant inputs that are observable, either directly or indirectly.

Level 3 — Valuations that require inputs that are both significant to the fair value measurement and unobservable.

Financial instruments are classified in their entirety within the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

Leases

The Company accounts for leases in accordance with ASC Topic 842, Leases (“ASC 842”). The Company’s leases primarily consist of real estate and laboratory equipment. At lease inception, the Company determines whether an arrangement contains a lease and classifies it as either an operating or finance lease. The Company’s operating and finance lease assets are included in right-of-use assets, net, and the current and non-current portions of the lease liabilities are included in lease liabilities and lease liabilities, non-current, respectively, on the Consolidated Balance Sheets. Right-of-use assets and lease liabilities are initially measured at the present value of future lease payments over the lease term, including fixed payments and certain in-substance fixed payments. Right-of-use assets are based on the corresponding lease liability, adjusted for (i) payments made at or before the commencement date, (ii) initial direct costs incurred, and (iii) tenant incentives under the lease. Variable lease payments that do not depend on an index or rate are excluded from the measurement of lease liabilities and are recognized as expense as incurred.

The Company does not account for renewals or early terminations unless it is reasonably certain that such options will be exercised at lease commencement. Lease modifications are accounted for in accordance with ASC 842 when the modification results in a separate contract or a remeasurement of the existing lease. The Company has elected the practical expedient to account for lease and non-lease components as a single lease component for both operating and finance leases.

Operating lease expense is recognized on a straight-line basis over the lease term. Finance lease right-of-use assets are amortized on a straight-line basis over the shorter of the lease term or the estimated useful life of the leased asset. The discount rate used to calculate the present value of lease liabilities is either the rate explicitly stated in the lease for finance leases or the Company’s incremental borrowing rate at the lease commencement date. The incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, in an economic environment where the leased asset is located. In determining the incremental borrowing rate, the Company considers factors including its credit rating, interest rates for similar debt instruments of entities with comparable credit ratings, the lease term, and the currency in which the lease is denominated.

The Company has elected the practical expedient to not recognize leases with a lease term of twelve months or less (“short-term leases”) on the balance sheet. Lease payments for such short-term leases are recognized as expense on a straight-line basis over the lease term.

Refer to Note 10, Leases, for additional information.

Research and Development Expenses

The Company expenses research and development costs as incurred in accordance with ASC 730, Research and Development. These costs primarily support discovery activities and the development of the Company’s product candidates and technology platform, including preclinical and clinical development of its development programs. Expenses include fees paid to third parties and contract research organizations (“CROs”), costs to manufacture materials for studies and trials, including payments to contract development and manufacturing organizations (“CDMOs”), and employee-related costs such as salaries, bonuses, benefits, and stock-based compensation. The Company also includes facilities-related costs, depreciation, and other direct or allocated expenses for rent, maintenance, and utilities, as well as licensing and license maintenance fees under agreements with no alternative future use and costs incurred to meet regulatory requirements.

The Company accrues expenses for research and development activities performed by third parties based on the level of services performed, the progress of studies (including the phase or completion of events), and contracted costs. Estimated costs of research and development provided but not yet invoiced are recorded in accrued expenses and other current liabilities on the Consolidated Balance Sheets. Accruals are adjusted as actual timing of services or levels of effort differ from estimates. Payments made to third parties in advance of the related services are recorded as prepaid expenses until the services are rendered. The Company estimates the period over which such services will be performed based on the terms of the agreements and the level of effort expected in each period.

Stock-Based Compensation Valuation and Expense

The Company measures all stock options and other stock-based awards granted to employees, non-employees, and directors based on the fair value on the date of the grant and recognizes compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award, in accordance with ASC Topic 718, Compensation – Stock Compensation (“ASC 718”) . Restricted stock units (“RSUs”) are measured and recognized over the vesting period based on the quoted market price of the Company’s common stock on the grant date.

The Company utilizes the Black-Scholes-Merton (“BSM”) option pricing model to determine the estimated fair value of stock options granted to employees and non-employees, including directors. In addition to the fair value of the Company’s common stock, the BSM model requires several key assumptions:

•

Expected Term—The expected life represents the period of time that the stock options are expected to be outstanding. Because the Company does not have substantial historical exercise behavior, it determines the expected term in accordance with the simplified method, which is an average of the contractual term of the stock option and its vesting period.

•

Expected Volatility— The estimated volatility is determined by evaluating the average historical volatility of a peer group of companies for the period preceding the stock option grant for a term that is approximately equal to the stock options’ expected term.

•

Risk-Free Interest Rate—The risk-free interest rate is based on the implied yield currently available on U.S. Treasury issues with a term that is equal to the stock options’ expected term at the grant date.

•

Expected Dividend—The expected dividend yield is assumed to be zero as the Company has not declared or paid dividends to date and does not anticipate declaring dividends for the foreseeable future.

The Company accounts for forfeitures as they occur. Stock-based compensation expense is recorded in research and development expense or general and administrative expense in the Consolidated Statements of Operations and Comprehensive Loss, based on the employee or non-employee’s functional role within the Company. See Note 8, Equity Incentive Plans, for additional information.

Income Taxes

The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic 740, Income Taxes (“ASC 740”), which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, the Company determined deferred tax assets and liabilities on the basis of the differences between the consolidated financial statements and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, it would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. Refer to Note 13, Income Taxes, for further information.

Net Loss per Share

Basic and diluted net loss per common share is calculated in accordance with ASC 260, Earnings per Share, by dividing net loss by the weighted-average number of common shares outstanding during the period. Potentially dilutive securities, including stock options and restricted stock units, are excluded from the computation of diluted net loss per share because their effect would be anti-dilutive for all periods presented. Refer to Note 9, Net Loss per Share, for the detailed computation of basic and diluted net loss per share and information regarding the potentially dilutive securities excluded from the computation.

Comprehensive Loss

Comprehensive loss is determined in accordance with ASC 220, Comprehensive Income, and includes net loss and other changes in stockholders’ equity resulting from transactions and economic events other than those with stockholders. For the Company, comprehensive loss consists of net loss plus foreign currency translation adjustments for all periods presented.

Recently Adopted Accounting Standards

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) (“ASU 2023-09”), which enhances the income tax disclosure requirements for public entities on an annual basis. Under ASU 2023-09, public entities will be required to disclose in their rate reconciliation, on an annual basis, both percentages and amounts in their reporting currency for certain categories in a tabular format, with accompanying qualitative disclosures. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, and early adoption is permitted. The Company adopted ASU 2023-09 during the year ended December 31, 2025. The adoption of this standard impacted the Company’s disclosures but did not have a material impact on its consolidated financial statements, results of operations, or financial position.

Recently Issued Accounting Standards Not Yet Adopted

In January 2025, the FASB issued ASU No. 2025-01 to clarify the effective date of ASU No. 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) (“ASU 2024-03”), which requires disaggregated disclosure of certain income statement captions within the footnotes to the financial statements. ASU 2025-01 requires adoption of the amendments of ASU 2024-03 in annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.

In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting (Topic 270) (“ASU 2025-11”) to clarify the applicability of ASC 270 and improve the organization of the guidance. The ASU clarifies when an entity is subject to interim reporting requirements and establishes disclosure principles for material events occurring since the end of the most recent annual reporting period. ASU 2025-11 is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.

In December 2025, the FASB issued ASU No. 2025-12, Improvements to Accounting Standards Codification (“ASU 2025-12”), which addresses stakeholder suggestions and makes incremental improvements to U.S. GAAP. The amendments clarify guidance, correct errors, and make minor improvements to the Accounting Standards Codification. ASU 2025-12 is effective for fiscal years beginning after December 15, 2026, including interim periods within those fiscal years. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.

Equity Incentive Plans - Summary of Stock Based Compensation Expense Regarding its Employees and Nonemployees (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Expense	$ 10,497	$ 3,491
General and administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Expense	6,003	2,309
Research and development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-Based Payment Arrangement, Expense	$ 4,494	$ 1,182

License agreements

12 Months Ended

Dec. 31, 2025

License Agreements [Abstract]

License Agreements

11. License agreements

Harvard Agreement

In July 2020, Tectonic entered into an agreement with the President and Fellows of Harvard College (“Harvard”), for an option fee in the low five digits, whereby Harvard granted Tectonic an exclusive option to negotiate a worldwide, exclusive, royalty-bearing license under Harvard’s interest in the patent rights covering certain technology that was developed by Harvard. In October 2021, Tectonic exercised the option and on February 10, 2022, entered into a license agreement (“License Agreement”) with Harvard to conduct research and development activities using certain materials, technology and patent rights owned by Harvard, with the intent to develop, obtain regulatory approval for, and commercialize products. The License Agreement will remain in effect until the expiration of the last valid

claim within the patent rights covering a product developed under the License Agreement or the termination of the License Agreement. The Company paid Harvard a one-time license fee and issued shares of common stock as consideration for the License Agreement.

The Company is responsible for payment of (1) annual maintenance fees ranging from the low five digits to the low six digits during the term of the License Agreement (through the first commercial sale of a royalty-bearing product); (2) milestone payments payable upon regulatory approval and the achievement of specified clinical and commercial milestones for licensed products or know-how enabled products; (3) royalty payments as a percentage in the low single digits of the annual net sales that the Company generates from products that utilize the license technology (“Licensed Products”) and royalty payments as a percentage in the low single digits of the annual net sales that the Company generates from know-how enabled product licenses (“Know-How Enabled Products”) and (4) a percentage between 10-20% of all non-royalty income received by the Company under sublicenses, strategic partnerships and know-how enabled product licenses that utilize the license technology. Subsequent to the first commercial sale of a royalty-bearing product, annual maintenance fees will increase to a low six digits for the remainder of the term of the License Agreement. The royalty term from sales of Licensed Products will terminate on a country-by-country and product-by-product basis on the earlier of (i) the expiration of the patent rights covering the product, expected to be no earlier than May 2041, and (ii) the termination of the License Agreement. The royalty term from sales of Know-How Enabled Products will terminate on the earlier of (i) ten years after the first commercial sale of the first Know-How Enabled Product and (ii) twelve years after the first commercial sale of the first Licensed Product. The Company incurred expense of $0.1 million and $0.4 million related to the License Agreement during the years ended December 31, 2025 and 2024, respectively.

INCOME TAXES - Schedule of Net (loss) Income Before Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Domestic Before income tax	$ (73,150)	$ (55,483)
Foreign Before income tax	229	(2,499)
Loss before income tax	$ (72,921)	$ (57,982)

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Nature of Business - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	12 Months Ended
	Jun. 20, 2024	Feb. 28, 2025	Dec. 31, 2025	Dec. 31, 2024
Nature Of Operations [Line Items]
Retained earnings (accumulated deficit)			$ 222,737	$ 148,586
Net Loss			$ 74,151	$ 57,982
Common Stock, Capital Shares Reserved for Future Issuance			3,434,874	2,775,878
Proceeds from Issuance or Sale of Equity, Total			$ 400,000
Proceeds received pursuant to agreement		$ 173,100
Cash and cash equivalents			$ 253,798	$ 141,239
ATM
Nature Of Operations [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance			100,000,000
Proceeds from the issuance of common stock			$ 100,000
Subscription Agreement [Member]
Nature Of Operations [Line Items]
Sale of stock issue price per share	$ 12.4
Proceeds from the issuance of common stock	$ 96,600
Subscription Agreement [Member] \| Avorbio Common Stock [Member]
Nature Of Operations [Line Items]
Stock issued during the period shares new issues converted pursuant to reverse recapitalization			4,163,606

Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Assets:
Assets	$ 253,498	$ 139,610
Money Market Funds [Member] \| Cash Equivalents [Member]
Assets:
Assets	253,498	139,610
Fair Value, Inputs, Level 1 [Member]
Assets:
Assets	253,498	0
Fair Value, Inputs, Level 1 [Member] \| Money Market Funds [Member] \| Cash Equivalents [Member]
Assets:
Assets	253,498	0
Fair Value, Inputs, Level 2 [Member]
Assets:
Assets	0	0
Fair Value, Inputs, Level 2 [Member] \| Money Market Funds [Member] \| Cash Equivalents [Member]
Assets:
Assets	0	0
Fair Value, Inputs, Level 3 [Member]
Assets:
Assets	0	139,610
Fair Value, Inputs, Level 3 [Member] \| Money Market Funds [Member] \| Cash Equivalents [Member]
Assets:
Assets	$ 0	$ 139,610

Leases - Schedule of Information About the Company's Leases (Detail)	Dec. 31, 2025	Dec. 31, 2024
Weighted-average remaining lease terms (in years)
Operating leases	15 years 6 months	8 years 5 months 26 days
Finance leases	10 years 29 days	9 years 9 months 3 days
Weighted-average discount rate
Operating leases	0.86%	1.06%
Finance leases	1.03%	2.26%

Cybersecurity Risk Management, Strategy, and Governance	12 Months Ended
Cybersecurity Risk Management, Strategy, and Governance	Dec. 31, 2025
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	Item 1C. Cybersecurity. Risk Management and Strategy We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and data related to our clinical trial and development of therapeutic proteins and antibodies (“Information Systems and Data”). Our Information Technology (“IT”) Department, led by our Vice President of IT, helps identify, assess and manage the Company’s cybersecurity threats and risks. Our IT Department identifies and assesses risks from cybersecurity threats by monitoring and evaluating our threat environment using various methods including, for example manual and automated tools, subscribing to reports and services that identify cybersecurity threats, analyzing reports of threats and threat actors, conducting scans of the threat environment, evaluating and assessing threats reported to us, coordinating with law enforcement about certain threats as may be appropriate, conducting internal and external audits and conducting risk and threat assessments. Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: our incident response plan, incident detection and response procedures, disaster recovery and business continuity plans, encryption of certain data, network security controls, data segmentation, access and physical security controls, asset management and disposal, monitoring of our systems, employee training, and maintaining cybersecurity insurance. Our assessment and management of material risks from cybersecurity threats are integrated into the Company’s overall risk management processes. For example, cybersecurity risk is addressed as a component of the Company’s enterprise risk management program and the IT Department works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business. We use third-party service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example cybersecurity consultants and managed cybersecurity providers. We use third-party service providers to perform a variety of functions throughout our business, such as application providers, hosting companies, and third parties associated with our clinical trial development, such as contract research organizations and contract manufacturing organizations. We have vendor management processes to manage cybersecurity risks associated with our use of certain of these providers. Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our vendor management process may involve different levels of assessment designed to help identify cybersecurity risks associated with a provider and impose contractual obligations related to cybersecurity on the provider. For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including if our information technology systems, or the information technology systems of our CROs, our CDMOs, service providers, our current and potential future partners or other third parties with whom we work were compromised, we could experience adverse consequences, including but not limited to material disruptions to our business operations, regulatory investigations or actions, litigation, fines and penalties, reputational harm, loss of revenue or profits, or other adverse consequences. Governance Our Board of Directors addresses the Company’s cybersecurity risk management as part of its general oversight function. The Board of Directors’ audit committee is responsible for overseeing Company’s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats. Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our VP of IT, who has over 25 years of IT experience and 10 years of cybersecurity management expertise. Our VP of IT is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company’s overall risk management strategy, and communicating key priorities to relevant personnel. Our Chief Financial Officer is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports. Our cybersecurity incident response plan is designed to escalate certain cybersecurity incidents to members of management depending on the circumstances. Management works with the Company’s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the Company’s incident response plan includes reporting to the audit committee of the Board of Directors for certain cybersecurity incidents as appropriate. The audit committee receives periodic reports our VP of IT concerning the Company’s significant cybersecurity threats and risk and the processes the Company has implemented to address them. The audit committee also can request access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	Our assessment and management of material risks from cybersecurity threats are integrated into the Company’s overall risk management processes. For example, cybersecurity risk is addressed as a component of the Company’s enterprise risk management program and the IT Department works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	Our Board of Directors addresses the Company’s cybersecurity risk management as part of its general oversight function. The Board of Directors’ audit committee is responsible for overseeing Company’s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Board of Directors’ audit committee is responsible for overseeing Company’s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats.
Cybersecurity Risk Role of Management [Text Block]	Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our VP of IT, who has over 25 years of IT experience and 10 years of cybersecurity management expertise. Our VP of IT is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company’s overall risk management strategy, and communicating key priorities to relevant personnel. Our Chief Financial Officer is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports. Our cybersecurity incident response plan is designed to escalate certain cybersecurity incidents to members of management depending on the circumstances. Management works with the Company’s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the Company’s incident response plan includes reporting to the audit committee of the Board of Directors for certain cybersecurity incidents as appropriate. The audit committee receives periodic reports our VP of IT concerning the Company’s significant cybersecurity threats and risk and the processes the Company has implemented to address them. The audit committee also can request access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	Our VP of IT is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company’s overall risk management strategy, and communicating key priorities to relevant personnel. Our Chief Financial Officer is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	who has over 25 years of IT experience and 10 years of cybersecurity management expertise.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	Our cybersecurity incident response plan is designed to escalate certain cybersecurity incidents to members of management depending on the circumstances. Management works with the Company’s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

Leases (Tables)

12 Months Ended

Dec. 31, 2025

Leases [Abstract]

Schedule of Components of Lease Expense and Other Information

The following table summarizes the components of lease costs for the years ended December 31, 2025 and 2024:


	Year Ended December 31,
	2025		2024
Operating lease cost:
Fixed lease cost	$	2,220	$	1,608

Finance lease cost:
Amortization of right-of-use assets		424		448
Interest on lease liabilities		63		107

Short-term lease costs		-		545

Variable lease costs		1,008		911
Total lease cost	$	3,715	$	3,619

The following table summarizes the lease assumptions for the years ended December 31, 2025 and 2024.


	Year Ended December 31,
	2025			2024
Weighted-average remaining lease terms in years
Operating leases		0.86			1.06
Finance leases		1.03			2.26
Weighted-average discount rate
Operating leases		15.50	%		8.49	%
Finance leases		10.08	%		9.76	%

Schedule of Future Commitments Due Under These Lease Agreements

Future commitments due under these lease agreements as of December 31, 2025 are as follows:


Year ended December 31,	Operating Leases			Finance Leases			Total
2026		948			363			1,311
2027		—			44			44
Thereafter		—			—			—
Total undiscounted cash flows		948			407			1,355
Less: interest		(59	)		(20	)		(79	)
Total lease liabilities	$	889		$	387		$	1,276
Less: current portion		(889	)		(344	)		(1,233	)
Lease liabilities	$	—		$	43		$	43

Future minimum lease payments of $5.3 million related to a lease entered into in September 2025 that had not commenced as of December 31, 2025 are excluded from the maturity table above, as no lease liability had been recognized as of that date.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION - Summary of reconciliation of cash, cash equivalents and restricted cash (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Cash and cash equivalents	$ 253,798	$ 141,239
Restricted cash	1,072	587
Total cash, cash equivalents and restricted cash	$ 254,870	$ 141,826	$ 29,356

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2025

Equity [Abstract]

Summary of Common Stock Reserved for Future Issuance

The Company reserved common stock for future issuance as follows:


	December 31, 2025		December 31, 2024
Outstanding options to purchase common stock		1,951,417		1,626,841
Unvested restricted stock units		262,184		25,612
Equity awards available for future issuance under the 2024 Equity Incentive Plan		925,367		976,082
Shares reserved for purchase under the 2024 Employee Stock Purchase Plan		295,906		147,343
Total		3,434,874		2,775,878

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-4

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-5

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481142/505-10-45-2

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-10

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-8

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-6

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-7

+ Details

Segment Information - Schedule of segment net loss and significant segment expenses (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2025

Dec. 31, 2024

Segment Reporting Information [Line Items]

Research and Development Expense

$ 63,489

$ 41,364

General and Administrative Expense

20,547

16,651

Total operating expenses

84,036

58,015

Net loss

(74,151)

(57,982)

Operating Segments [Member]

Segment Reporting Information [Line Items]

Non-controllable expenses

8,985

8,733

Other income

^[1]

2,139

5,134

Net loss

74,151

57,982

Operating Segments [Member] | Employee Related Expenses [Member]

Segment Reporting Information [Line Items]

Research and Development Expense

12,961

11,135

General and Administrative Expense

5,548

5,553

Operating Segments [Member] | Research and Pre-clinical Expenses [Member]

Segment Reporting Information [Line Items]

Research and Development Expense

7,001

8,477

Operating Segments [Member] | Clinical and Development Expenses [Member]

Segment Reporting Information [Line Items]

Research and Development Expense

23,798

15,380

Operating Segments [Member] | Non-ClinicalScienceExpenses[Member]

Segment Reporting Information [Line Items]

Research and Development Expense

3,667

Operating Segments [Member] | Chemistry, Manufacturing, and Control Expenses [Member]

Segment Reporting Information [Line Items]

Research and Development Expense

$ 10,052

$ 3,570

[1]

Other segment expenses include expenses not captured in the primary employee-related, research and development, or general and administrative categories, such as stock-based compensation, depreciation and amortization, changes in the fair value of SAFE liabilities, income tax expense, interest income and interest expense.

Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details) - shares	Dec. 31, 2025	Dec. 31, 2024
Class of Stock [Line Items]
Total shares of authorized common stock reserved for future issuance	3,434,874	2,775,878
Stock Options to Purchase Common Stock [Member]
Class of Stock [Line Items]
Total shares of authorized common stock reserved for future issuance	1,951,417	1,626,841
Restricted Stock Units [Member]
Class of Stock [Line Items]
Total shares of authorized common stock reserved for future issuance	262,184	25,612
2024 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Total shares of authorized common stock reserved for future issuance	925,367	976,082
2024 Employee Stock Purchase Plan [Member]
Class of Stock [Line Items]
Total shares of authorized common stock reserved for future issuance	295,906	147,343

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef
-Topic 272
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483014/272-10-45-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 272
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482987/272-10-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

+ Details

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Cash flows from operating activities:
Net loss	$ (74,151)	$ (57,982)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	1,375	1,645
Stock-based compensation expense	10,497	3,491
Loss on sale of property and equipment	153	0
Reduction in the carrying amount of the operating right-of-use assets	2,118	434
Change in fair value of SAFE liabilities	0	3,610
Change in operating assets and liabilities:
Prepaid expenses and other current assets	2,644	(3,194)
Other non-current assets	17	544
Accounts payable	116	(1,421)
Accrued expenses and other current liabilities	(552)	(5,642)
Operating lease liabilities	(2,295)	(565)
Net cash used in operating activities	(60,078)	(59,080)
Cash flows from investing activities:
Purchase of property and equipment	(208)	(156)
Proceeds from the sale of property and equipment	70	0
Net cash used in investing activities	(138)	(156)
Cash flows from financing activities:
Proceeds from the private placement, net of offering costs of $11,928	173,098	0
Proceeds from the Subscription Agreement, net of offering costs of $2,000	0	94,600
Cash acquired in connection with the Merger, net of transaction costs of $7,412	0	75,965
Proceeds from exercise of stock options	1,231	1,624
Payments for employee taxes related to net share settlement of equity awards	(17)	0
Payment of deferred offering costs	(468)	0
Repayment of finance lease obligations	(489)	(475)
Net cash provided by financing activities	173,355	171,714
Effect of exchange rate changes on cash and cash equivalents	(95)	(8)
Net increase in cash and cash equivalents and restricted cash	113,044	112,470
Cash and cash equivalents and restricted cash as of beginning of period	141,826	29,356
Cash and cash equivalents and restricted cash as of end of period	254,870	141,826
Components of cash, cash equivalents and restricted cash:
Cash and cash equivalents	253,798	141,239
Restricted cash	1,072	587
Total cash, cash equivalents and restricted cash	254,870	141,826
Supplemental disclosure of cash flow information:
Deferred offering costs included in accrued expenses and other liabilities	35	0
Right-of-use assets obtained in exchange for new operating lease liabilities	757	0
Conversion of SAFEs to Common Stock	0	34,125
Conversion of Convertible Preferred Stock to Common Stock	$ 0	$ 80,627

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2025

Fair Value Disclosures [Abstract]

Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis


	December 31, 2025
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents:
Money market funds	$	253,498	$	—	$	—	$	253,498
Total assets	$	253,498	$	—	$	—	$	253,498


	December 31, 2024
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents:
Money market funds	$	139,610	$	—	$	—	$	139,610
Total assets	$	139,610	$	—	$	—	$	139,610

Money market funds are included in cash and cash equivalents on the Consolidated Balance Sheets and are measured at fair value on a recurring basis. These instruments are classified within Level 1 of the fair value hierarchy because they are valued using quoted prices in active markets for identical assets.

Summary of Activity for the Safe Liabilities that were Measured at Fair Value

The following table presents activity for the SAFE liabilities that were measured at fair value using significant unobservable Level 3 inputs during the year ended December 31, 2024:


	SAFE Liabilities
Balance as of January 1, 2024		30,515
Fair value adjustments		3,610
Redemption		(34,125	)
Balance as of December 31, 2024	$	—

Equity Incentive Plans (Tables)

12 Months Ended

Dec. 31, 2025

Share-Based Payment Arrangement [Abstract]

Summary of The Stock Option Activity

The following table summarizes the stock option activity under the 2019 Plan and 2024 Plan for the year ended December 31, 2025:


	Outstanding Options
	Number of Shares Underlying Outstanding Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding as of January 1, 2025		1,534,361		$	12.49
Options granted		559,873			35.21
Options exercised		(114,558	)		2.91			$	3,240
Options forfeited and expired		(28,259	)		14.27
Outstanding as of December 31, 2025		1,951,417		$	19.55		8.2	$	12,532
Options vested and exercisable as of December 31, 2025		792,535		$	13.45		7.5	$	8,004
Options vested and expected to vest as of December 31, 2025		1,951,417		$	19.55		8.2	$	12,532

The following table summarizes the stock option activity for the options that were assumed from AVROBIO upon the Merger closing for the year ended December 31, 2025:


	Outstanding Options
	Number of Shares Underlying Outstanding Options			Weighted- Average Exercise Price		Aggregate Intrinsic Value
Outstanding as of January 1, 2025		92,480		$	22.69
Options exercised		(71,215	)		12.61	$	2,099
Options forfeited and expired		(21,265	)		56.44
Outstanding as of December 31, 2025		—		$	—	$	—
Options vested and exercisable as of December 31, 2025		—		$	—	$	—
Options vested and expected to vest as of December 31, 2025		—		$	—	$	—

Summary of Fair Values of the Options Granted

The following table summarizes the assumptions used for estimating the fair value of stock options granted under the BSM option-pricing model:


	Year Ended December 31,
	2025	2024
Expected term (in years)	5.50 - 6.25	6.00 - 6.25
Expected volatility	102.6% - 103.7%	100.0% - 104.0%
Risk-free interest rate	3.76% - 4.43%	4.10% - 4.26%
Expected dividend yield	0%	0%

Summary of Restricted Stock Activity

The following table summarizes the RSU activity for the year ended December 31, 2025:


	Outstanding RSUs
	Number of Shares Underlying Outstanding Units			Weighted- Average Grant Date Fair Value per Unit
Outstanding as of January 1, 2025		25,612		$	44.90
Restricted stock units granted		246,262			36.13
Restricted stock units vested		(7,561	)		44.08
Restricted stock units forfeited		(2,129	)		48.01
Outstanding as of December 31, 2025		262,184		$	36.66
Unvested and expected to vest as of December 31, 2025		262,184		$	36.66

Summary of Stock Based Compensation Expense Regarding its Employees and Nonemployees

The following table is a summary of stock-based compensation expense recognized by function:


	Year Ended December 31,
	2025		2024
General and administrative	$	6,003	$	2,309
Research and development		4,494		1,182
Total stock-based compensation expense	$	10,497	$	3,491

Summary of the unrecognized compensation expense and weighted-average remaining period

The following table summarizes the unrecognized compensation expense and the weighted-average remaining period over which it is expected to be recognized, by type of award:


	As of December 31, 2025
	Unamortized Expense		Weighted Average Remaining Recognition Period (Years)
Stock options		21,445		2.5
RSUs		7,163		2.3

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Private Placement [Member]	Private Placement [Member] Common Stock [Member]	Convertible Preferred Stock [Member] Preferred Stock [Member]
Beginning balance at Dec. 31, 2023	$ (84,636)	$ 0	$ 5,979	$ (11)	$ (90,604)			$ 80,627
Beginning balance (in shares) at Dec. 31, 2023		1,407,753						3,647,675
Exercise of stock options	1,624		1,624
Exercise of stock options (in shares)		388,727
Stock-based compensation expense	3,491		3,491
Stock Issued During Period, Value, Restricted Stock Award, Gross	15		15
Conversion of convertible preferred stock into common stock in connection with the Merger	80,627		80,627					$ (80,627)
Conversion of convertible preferred stock into common stock in connection with the Merger (in shares)		3,647,675						(3,647,675)
Issuance of common stock to related party investors upon redemption of the SAFEs	34,125		34,125
Issuance of common stock to related party investors upon redemption of the SAFEs (in shares)		1,470,839
Issuance of common stock under subscription agreement	94,601	$ 1	94,600
Issuance of common stock under subscription agreement (in shares)		4,163,606
Issuance of common stock upon the merger	68,891	$ 1	68,890
Issuance of common stock upon the merger (in shares)		3,777,709
Foreign currency translation adjustment	20			20
Net Income (Loss)	(57,982)				(57,982)
Ending balance at Dec. 31, 2024	140,776	$ 2	289,351	9	(148,586)			$ 0
Ending balance (in shares) at Dec. 31, 2024		14,856,309						0
Exercise of stock options	$ 1,231		1,231
Exercise of stock options (in shares)	71,215	185,773
Stock-based compensation expense	$ 10,497		10,497
Issuance of common stock upon vesting of restricted stock units, Share		6,702
Stock Issued During Period, Value, Restricted Stock Award, Gross	17		17
Stock issued during the period shares new issues							3,689,465
Stock Issued During Period Value						$ 173,098	$ 173,098
Foreign currency translation adjustment	(105)			(105)
Net Income (Loss)	(74,151)				(74,151)
Ending balance at Dec. 31, 2025	$ 251,329	$ 2	$ 474,160	$ 96	$ (222,737)			$ 0
Ending balance (in shares) at Dec. 31, 2025		18,738,249						0

Merger (Tables)

12 Months Ended

Dec. 31, 2025

Business Combination [Abstract]

Summary of the Recognized Assets and Liabilities

As part of the recapitalization, Legacy Tectonic recognized the assets and liabilities listed below:


Cash and cash equivalents	$	85,230
Prepaid expenses and other current assets		319
Accounts payable		(1,988	)
Accrued expenses and other current liabilities		(5,405	)
Net assets acquired	$	78,156

- Definition

Tabular disclosure of business combination. Includes, but is not limited to, recognized asset and liability.

+ References + Details

Accrued Expenses and Other Current Liabilities

12 Months Ended

Dec. 31, 2025

Payables and Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities is comprised of the following:


	December 31, 2025		December 31, 2024
Accrued compensation and related expenses	$	4,110	$	3,585
Accrued research and development expenses		2,301		2,787
Accrued other expenses		929		1,478
Total accrued expenses and other current liabilities	$	7,340	$	7,850

Income Taxes - Schedule Of Components of Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Income Taxes [Line Items]
Federal Current Expenses	$ 0	$ 0
State Current Expense	45	0
Foreign Current Expense	1,185	0
Total current expense (benefit):	1,230	0
Federal Deferred Expense	14,931	13,004
State Deferred Expense	4,127	3,181
Foreign Deferred Expense	(380)	741
Deferred Tax Benefit	18,678	16,926
Less change in valuation allowance	(18,678)	(16,926)
Total income tax expense (benefit)	$ (1,230)	$ 0

Property and Equipment, Net - Summary of Property and Equipment Net (Detail) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Property, Plant and Equipment [Line Items]
Property plant and equipment gross	$ 4,592	$ 4,896
Less: accumulated depreciation	(3,407)	(2,745)
Property and equipment, net	1,185	2,151
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment gross	4,286	4,590
Office equipment, furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment gross	281	281
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment gross	$ 25	$ 25

Fair Value Measurements - Summary of Activity for the Safe Liabilities that were Measured at Fair Value (Detail) - SAFE Liabilities [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance as of January 1, 2024	$ 30,515
Fair value adjustments	3,610
Redemption	(34,125)
Balance as of December 31, 2024	$ 0

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2025	Dec. 31, 2024
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Par Value	$ 0.0001	$ 0.0001
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, authorized	150,000,000	150,000,000
Common stock, issued	18,738,249	14,856,309
Common stock, outstanding	18,738,249	14,856,309

Stockholders' Equity

12 Months Ended

Dec. 31, 2025

Equity [Abstract]

Stockholders' Equity

7. STOCKHOLDERS’ EQUITY

Common Stock

The Company is authorized to issue 150,000,000 shares of common stock at a par value of $0.0001 per share. Holders of voting common stock are entitled to one vote per share. In addition, holders of voting common stock are entitled to receive dividends, if and when declared by the Company’s Board of Directors. As of December 31, 2025, no dividends have been declared.

The Company reserved common stock for future issuance as follows:


	December 31, 2025		December 31, 2024
Outstanding options to purchase common stock		1,951,417		1,626,841
Unvested restricted stock units		262,184		25,612
Equity awards available for future issuance under the 2024 Equity Incentive Plan		925,367		976,082
Shares reserved for purchase under the 2024 Employee Stock Purchase Plan		295,906		147,343
Total		3,434,874		2,775,878

Preferred Stock

The Company is authorized to issue 10,000,000 shares of undesignated preferred stock at a par value of $0.0001 per share, however no such shares were issued or outstanding as of December 31, 2025.

Convertible Preferred Stock

Prior to the conversion upon the closing of the Merger, Legacy Tectonic issued Series A-1, A-2, A-3 and A-4 convertible preferred stock (the “Convertible Preferred Stock”). Upon the closing of the Merger, all outstanding shares of the Convertible Preferred Stock were converted into 3,647,675 shares of common stock. No shares of Convertible Preferred Stock are authorized for issuance as of December 31, 2025.

Changes in Capital Structure

In February 2025, the Company entered into a securities purchase agreement (the “Private Placement”) pursuant to which the Company issued an aggregate of 3,689,465 shares of common stock, at a price of $50.00 per share to institutional accredited investors and $54.14 per share to individual accredited investors that are either an officer or director of the Company. The net proceeds from the Private Placement were approximately $173.1 million.

Upon the closing of the Merger as described in Note 3, Merger, all outstanding shares of convertible preferred stock were converted into an aggregate of 3,647,675 shares of the Company’s common stock and $80.6 million of mezzanine equity was reclassified to common stock and additional paid-in capital. As of December 31, 2024, there were no shares of convertible preferred stock issued or outstanding.

Upon the closing of the Merger, the principal balance of the SAFE instruments was automatically redeemed for 2,752,216 shares of Legacy Tectonic common stock at the conversion price of $12.40 per share immediately prior to the Merger closing. At closing, shares of Legacy Tectonic common stock issued pursuant to the redemption of Legacy Tectonic SAFEs were converted into 1,470,839 shares of common stock based on the Exchange Ratio, pursuant to the Merger Agreement.

Concurrently with the closing of the Merger, on June 20, 2024, certain investors completed the purchase of shares of Legacy Tectonic common stock pursuant to the Subscription Agreement at a price of $12.40 per share for an aggregate purchase price of $96.6 million. The shares of Legacy Tectonic common stock that were issued pursuant to the Subscription Agreement were converted into 4,163,606 shares of common stock upon the closing of the Merger based on the exchange ratio, pursuant to the Merger Agreement.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Segment Information

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Segment information

16. SEGMENT INFORMATION

The Company operates in one operating segment, and therefore one reportable segment, focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. The accounting policies of the segment are the same as those described in the summary of significant accounting policies.

The determination of a single segment is consistent with the consolidated financial information regularly reviewed by the Chief Executive Officer, who serves as the CODM, in evaluating financial performance and allocating resources on a consolidated basis. The CODM primarily evaluates the Company’s performance based on net loss and significant expense categories.

No segment asset information is presented because the CODM focuses on cash and expense impact; segment assets are monitored at the same level as the Consolidated Balance Sheet.

The following table presents the segment net loss and significant segment expenses for the years ended December 31, 2025 and 2024:


	Year Ended December 31,
	2025		2024
Employee-related expenses:
Research and development employee-related expenses	$	12,961	$	11,135
General and administrative employee-related expenses		5,548		5,553

External research and development expenses:
Research and preclinical expenses		7,001		8,477
Clinical and development expenses		23,798		15,380
Chemistry, manufacturing, and control expenses		10,052		3,570
Non-clinical science expenses		3,667		—

Non-employee-related general and administrative expenses		8,985		8,733
Other segment items1		2,139		5,134
Net loss	$	74,151	$	57,982

1 Other segment expenses include expenses not captured in the primary employee-related, research and development, or general and administrative categories, such as stock-based compensation, depreciation and amortization, changes in the fair value of SAFE liabilities, income tax expense, interest income and interest expense.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Nature of Business

12 Months Ended

Dec. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Business

1. NATURE OF BUSINESS

Description of the Business

Tectonic Therapeutic, Inc. (formerly AVROBIO, Inc.) (the “Company” or “Tectonic”) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”). Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life.

Merger

On June 20, 2024, the Company completed its previously announced merger transaction in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of January 30, 2024 (the “Merger Agreement”) with AVROBIO, Inc. (“AVROBIO”), pursuant to which Alpine Merger Subsidiary, Inc., a wholly owned subsidiary of AVROBIO, merged with and into the entity formerly known as Tectonic Therapeutic, Inc., now known as Tectonic Operating Company, Inc. (“Legacy Tectonic”), with Legacy Tectonic continuing as a wholly owned subsidiary of the surviving corporation of AVROBIO (the “Merger”). The Merger was accounted for as a reverse recapitalization in accordance with generally accepted accounting principles in the United States of America (“GAAP”), with AVROBIO treated as the acquired company for financial reporting purposes, and Legacy Tectonic treated as the accounting acquirer. Accordingly, the historical financial statements prior to the Merger reflect those of Legacy Tectonic.

Risks and Uncertainties

The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure, and extensive compliance reporting capabilities.

The Company’s proprietary GEODe™ platform is currently in development. There can be no assurance that current and future research and development activities will be successfully completed, that adequate protection for owned intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies.

Liquidity and Capital Resources

Since inception, the Company has incurred recurring losses and negative cash flows from operations and expects such losses to continue in the future as it conducts research and development activities and continues to develop its product candidates. The Company generated net losses of $74.2 million and $58.0 million for the years ended December 31, 2025 and 2024, respectively and had an accumulated deficit of $222.7 million as of December 31, 2025. The Company has financed its operations primarily through the sale and issuance of common stock, convertible equity instruments, and the Merger. In February 2025, the Company sold shares of its common stock under a securities purchase agreement in exchange for net proceeds of approximately $173.1 million. The Company has devoted substantially all of its financial resources and efforts to business planning, conducting research and development, recruiting management and technical staff, and raising capital. The Company also has an effective shelf registration statement on Form S-3 filed with the SEC, which may be used to offer from time to time any combination of common stock, preferred stock, debt securities, and warrants up to an aggregate amount of $400 million. Of this amount, the Company has the ability to sell up to $100 million of additional shares of common stock to the public through an at the market offering (“ATM”). During the year ended December 31, 2025, the Company did not sell any shares under the ATM program. As of December 31, 2025, the full $100 million remained available for issuance under the ATM program.

As the Company continues to develop its proprietary platform and potential product candidates, it will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. It may never achieve profitability, and unless and until it does, it will continue to need to raise additional capital to fund its operations. The Company had cash and cash equivalents of $253.8 million as of December 31, 2025. In accordance with Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.

The Company believes that its existing cash and cash equivalents will be sufficient to allow the Company to fund operations beyond twelve months from the date of issuance of these consolidated financial statements.

Leases

12 Months Ended

Dec. 31, 2025

Leases [Abstract]

Leases

10. Leases

The Company has lease obligations, including amounts due on leases of certain laboratory equipment and office and laboratory space under the terms of non-cancelable operating and finance leases.

Office and Laboratory Facilities Lease

In November 2020, the Company executed a facilities lease agreement to occupy approximately 19,000 square feet of office and laboratory space, which was subsequently amended on April 21, 2022. The lease requires the Company to pay fixed base rent, which is included in the measurement of the lease, as well as its proportionate share of the facilities operating expenses, which are treated as variable lease costs based on the Company’s election to combine lease and associated non-lease components and are excluded from the measurement of the lease. The lease expires on January 31, 2026, and, consistent with the Company’s current facilities plan noted below, will not be renewed. Operating lease cost is allocated between research and development and general and administrative expenses based on the usage of the leased facilities. The Company recognizes variable lease costs for operating leases, including its proportionate share of facilities operating expenses. These costs are excluded from the measurement of the lease liability. The reported lease term excludes the Company’s renewal options under its office and laboratory lease agreements, as the Company does not consider it reasonably certain to exercise the options.

The Company also has a limited operating lease arrangement for laboratory space that provides the right to use designated research premises through December 31, 2026. The Company initially entered into the lease in December 2023 for a one-year term. The lease term has subsequently been extended pursuant to amendments executed in the ordinary course of business, including an amendment entered into in December 2025 that extended the term through December 31, 2026. The Company has recognized a corresponding right-of-use asset and lease liability of $0.8 million on its Consolidated Balance Sheet related to this arrangement. The lease requires the Company to pay fixed base rent, which is included in the measurement of the lease liability.

Laboratory Equipment Leases

The Company has entered into various financing leases for laboratory equipment used in research and development activities.

Future Lease Commencements

In September 2025, the Company entered into a non-cancelable operating lease for office and laboratory space in Watertown, Massachusetts. The total future minimum lease payments under this agreement are approximately $5.3 million over the lease term of three years. As of December 31, 2025, the lease has not yet commenced, and therefore no right-of-use asset or lease liability has been recognized on the Company’s Consolidated Balance Sheet. The lease will be recorded on the balance sheet upon commencement in January 2026, at which time the Company will recognize a right-of-use asset and corresponding lease liability based on the present value of lease payments over the lease term.

The following table summarizes the components of lease costs for the years ended December 31, 2025 and 2024:


	Year Ended December 31,
	2025		2024
Operating lease cost:
Fixed lease cost	$	2,220	$	1,608

Finance lease cost:
Amortization of right-of-use assets		424		448
Interest on lease liabilities		63		107

Short-term lease costs		-		545

Variable lease costs		1,008		911
Total lease cost	$	3,715	$	3,619

The following table summarizes the lease assumptions for the years ended December 31, 2025 and 2024.


	Year Ended December 31,
	2025			2024
Weighted-average remaining lease terms in years
Operating leases		0.86			1.06
Finance leases		1.03			2.26
Weighted-average discount rate
Operating leases		15.50	%		8.49	%
Finance leases		10.08	%		9.76	%

Future commitments due under these lease agreements as of December 31, 2025 are as follows:


Year ended December 31,	Operating Leases			Finance Leases			Total
2026		948			363			1,311
2027		—			44			44
Thereafter		—			—			—
Total undiscounted cash flows		948			407			1,355
Less: interest		(59	)		(20	)		(79	)
Total lease liabilities	$	889		$	387		$	1,276
Less: current portion		(889	)		(344	)		(1,233	)
Lease liabilities	$	—		$	43		$	43

Stockholders' Equity - Additional Information (Detail) - USD ($)		1 Months Ended	12 Months Ended
	Jun. 20, 2024	Feb. 28, 2025	Dec. 31, 2025	Dec. 31, 2024
Class of Stock [Line Items]
Reclassification of euity upon conversion				$ 80,627,000
Common stock, authorized			150,000,000	150,000,000
Common stock, par value			$ 0.0001	$ 0.0001
Common stock, issued			18,738,249	14,856,309
Common stock, outstanding			18,738,249	14,856,309
Common stock, voting rights			holders of voting common stock are entitled to receive dividends
Common stock, dividends, per share, declared			$ 0
SAFE [Member]
Class of Stock [Line Items]
Common stock, par value	$ 12.4		$ 12.4
Common stock, issued	2,752,216		2,752,216
Subscription Agreement [Member]
Class of Stock [Line Items]
Sale of stock issue price per share	$ 12.4
Proceeds from the issuance of common stock	$ 96,600,000
AVROBIO \| SAFE [Member]
Class of Stock [Line Items]
Common stock, issued				1,470,839
Avorbio Common Stock [Member] \| Subscription Agreement [Member]
Class of Stock [Line Items]
Stock issued during the period shares new issues converted pursuant to reverse recapitalization			4,163,606
Preferred Stock [Member]
Class of Stock [Line Items]
Common stock issuable upon conversion		3,689,465	3,647,675	3,647,675
Reclassification of euity upon conversion				$ 80,600,000
Convertible Preferred stock, outstanding				0
Convertible preferred stock authorized for issuance			0
Convertible Preferred stock, issued				0
Common stock, par value		$ 50
Preferred Stock [Member] \| Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Common stock, par value		$ 54.14
Proceeds from the issuance of common stock		$ 173,100,000
Common Stock [Member]
Class of Stock [Line Items]
Common stock, authorized			150,000,000
Common stock, par value			$ 0.0001
Undesignated Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Par Value			$ 0.1000
Unrestricted Common Stock [Member]
Class of Stock [Line Items]
Preferred stock, authorized			10,000,000

Fair Value Measurements

12 Months Ended

Dec. 31, 2025

Fair Value Disclosures [Abstract]

Fair Value Measurements

4. FAIR VALUE MEASUREMENTS

The following tables present information about financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:


	December 31, 2025
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents:
Money market funds	$	253,498	$	—	$	—	$	253,498
Total assets	$	253,498	$	—	$	—	$	253,498


	December 31, 2024
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents:
Money market funds	$	139,610	$	—	$	—	$	139,610
Total assets	$	139,610	$	—	$	—	$	139,610

There were no transfers between the Level 1, Level 2 or Level 3 categories during the years ended December 31, 2025 and 2024.

The carrying amounts reflected in the Company's Consolidated Balance Sheets for prepaid expenses and other current assets, accounts payable, and accrued expenses and other current liabilities approximate their fair values, due to their short-term nature.

SAFE Liabilities

From October through December 2023, Legacy Tectonic entered into multiple SAFE agreements with certain existing investors and received proceeds of $34.1 million. Prior to redemption, the SAFE liabilities were valued using a probability weighted scenario analysis and discount rates derived by application of the build-up method to reflect the cost of equity. The valuation model required a variety of inputs, including the probability of occurrence of events that would trigger conversion or redemption of the SAFEs, the expected timing of such events, and a discount rate.

Upon the closing of the Merger, the principal balance of the SAFE instruments was automatically redeemed for 2,752,216 shares of Legacy Tectonic common stock at the conversion price of $12.40 per share immediately prior to the Merger closing. As such the valuation inputs utilized to adjust the SAFE liability to fair value upon the closing of the Merger was $12.40. At closing, shares of Legacy Tectonic common stock issued pursuant to the redemption of Legacy Tectonic SAFEs were converted into 1,470,839 shares of AVROBIO common stock based on the Exchange Ratio, pursuant to the Merger Agreement. No level 3 instruments remain outstanding after the Merger.

The following table presents activity for the SAFE liabilities that were measured at fair value using significant unobservable Level 3 inputs during the year ended December 31, 2024:


	SAFE Liabilities
Balance as of January 1, 2024		30,515
Fair value adjustments		3,610
Redemption		(34,125	)
Balance as of December 31, 2024	$	—

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

INCOME TAXES - Schedule of Net Company's Income Taxes Paid of Refunds Received (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Income Tax Paid, by Individual Jurisdiction [Line Items]
Income tax paid Federal	$ 0	$ 0
Income tax paid State	45	0
Income tax paid Foreign	1,185	0
Total income tax paid, net	1,230	$ 0
Australia
Income Tax Paid, by Individual Jurisdiction [Line Items]
Total income tax paid, net	$ 1,185

Leases - Schedule of Components of Lease Expense and Other Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Lease, Cost [Abstract]
Finance lease amortization of right-of-use assets	$ 424	$ 448
Interest of finance lease liabilities	63	107
Finance lease expense	2,220	1,608
Short-term lease expense	0	545
Variable lease expense	1,008	911
Total lease expense	$ 3,715	$ 3,619

Property and Equipment, Net

12 Months Ended

Dec. 31, 2025

Property, Plant and Equipment [Abstract]

Property and Equipment, Net

5. PROPERTY and EQUIPMENT, NET

Property and equipment, net is comprised of the following:


	December 31, 2025			December 31, 2024
Laboratory equipment	$	4,286		$	4,590
Office equipment, furniture and fixtures		281			281
Leasehold improvements		25			25
		4,592			4,896
Less: accumulated depreciation		(3,407	)		(2,745	)
Property and equipment, net	$	1,185		$	2,151

Depreciation expense was $1.0 million and $1.2 million for the years ended December 31, 2025 and 2024, respectively, and is primarily attributable to research and development activities.

Merger - (Additional Information) (Detail) $ in Millions	12 Months Ended
Merger - (Additional Information) (Detail) $ in Millions	Dec. 31, 2024 USD ($)
Merger [Line Items]
Reduction to additional paid-in capital	$ 9.3

Related Party Transactions - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2025	Dec. 31, 2024
Related Party Transaction [Line Items]
Research and development		$ 63,489	$ 41,364
Proceeds from the issuance of SAFEs	$ 34,100
SAFE related party, outstanding amount		0	0
License Agreement [Member]
Related Party Transaction [Line Items]
Amount Due to Related Party		0	0
Research and development		100	400
Member of the Scientific Advisory Board [Member] \| Advisory Services Agreement [Member]
Related Party Transaction [Line Items]
Professional fees		100	100
Amount Due to Related Party		$ 0	$ 0
Private Placement [Member]
Related Party Transaction [Line Items]
Sale of stock issue price per share		$ 54.14

Equity Incentive Plans

12 Months Ended

Dec. 31, 2025

Share-Based Payment Arrangement [Abstract]

Equity Incentive Plans

8. EQUITY INCENTIVE PLANS

2019 Equity Incentive Plan

The Legacy Tectonic 2019 Equity Incentive Plan (the “2019 Plan”) provides employees, consultants and advisors and non-employee members of the Board of Directors with the opportunity to receive grants of stock options, stock awards and equity awards. Following the effectiveness of the 2024 Equity Incentive Plan as described below, no further grants are to be made under the 2019 Plan; however, outstanding equity awards granted under the 2019 Plan continue to be governed by the terms of the 2019 Plan.

2024 Equity Incentive Plan

On June 20, 2024, the Company adopted the 2024 Equity Incentive Plan (the “2024 Plan”) which became effective upon completion of the Merger. The 2024 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, consultants, and non-employee directors of the Company. The number of shares of common stock available for issuance under the 2024 Plan will automatically increase on January 1st of each year through January 1, 2034, in an amount equal to the lesser of (a) 5% of the total number of shares of common stock issued and outstanding determined as of the day prior to such increase, or (b) an amount determined by the Board of Directors. On January 1, 2026, the number of shares of common stock available for issuance under the 2024 Plan automatically increased by 936,912 shares.

2024 Employee Stock Purchase Plan

On June 20, 2024, the Company adopted the 2024 Employee Stock Purchase Plan (the “ESPP”), which became effective upon completion of the Merger. The number of shares of our common stock available for issuance under the ESPP will automatically increase on January 1st of each year through 2034, in an amount equal to the lesser of (a) 1% of the total number of shares of common stock issued and outstanding determined as of the day prior to such increase, (b) a number of shares qual to three times the initial share reserve , or (c) an amount determined by the Board of Directors. On January 1, 2026, the number of shares of common stock available for issuance under the ESPP increased by 187,382 shares. No offering periods under the ESPP have been initiated as of December 31, 2025.

Stock Options

Stock options granted to employees generally vest over a four-year period in multiple tranches and have a contractual term of ten years. Options granted to the Board of Directors generally vest over a one-year period.

The following table summarizes the stock option activity under the 2019 Plan and 2024 Plan for the year ended December 31, 2025:


	Outstanding Options
	Number of Shares Underlying Outstanding Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding as of January 1, 2025		1,534,361		$	12.49
Options granted		559,873			35.21
Options exercised		(114,558	)		2.91			$	3,240
Options forfeited and expired		(28,259	)		14.27
Outstanding as of December 31, 2025		1,951,417		$	19.55		8.2	$	12,532
Options vested and exercisable as of December 31, 2025		792,535		$	13.45		7.5	$	8,004
Options vested and expected to vest as of December 31, 2025		1,951,417		$	19.55		8.2	$	12,532

During the years ended December 31, 2025 and 2024, the Company granted options with a weighted-average grant-date fair value of $29.04 and $14.90 per share, respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2025 and 2024 was $3.2 million and $5.6 million, respectively.

The following table summarizes the stock option activity for the options that were assumed from AVROBIO upon the Merger closing for the year ended December 31, 2025:


	Outstanding Options
	Number of Shares Underlying Outstanding Options			Weighted- Average Exercise Price		Aggregate Intrinsic Value
Outstanding as of January 1, 2025		92,480		$	22.69
Options exercised		(71,215	)		12.61	$	2,099
Options forfeited and expired		(21,265	)		56.44
Outstanding as of December 31, 2025		—		$	—	$	—
Options vested and exercisable as of December 31, 2025		—		$	—	$	—
Options vested and expected to vest as of December 31, 2025		—		$	—	$	—

As of December 31, 2025, no unexercised or outstanding stock options related to the Merger remain.

Fair Value of Stock Options Granted

The Company utilizes the BSM option-pricing model to determine the fair value of stock options granted.

The following table summarizes the assumptions used for estimating the fair value of stock options granted under the BSM option-pricing model:


	Year Ended December 31,
	2025	2024
Expected term (in years)	5.50 - 6.25	6.00 - 6.25
Expected volatility	102.6% - 103.7%	100.0% - 104.0%
Risk-free interest rate	3.76% - 4.43%	4.10% - 4.26%
Expected dividend yield	0%	0%

Restricted Stock Units

Restricted stock units (“RSUs”), which are granted to employees, generally vest over a three-year period. The value of an RSU award is based on the quoted market price of the Company's stock on the grant date. The shares underlying the RSUs are not issued until the RSUs vest. The following table summarizes the RSU activity for the year ended December 31, 2025:


	Outstanding RSUs
	Number of Shares Underlying Outstanding Units			Weighted- Average Grant Date Fair Value per Unit
Outstanding as of January 1, 2025		25,612		$	44.90
Restricted stock units granted		246,262			36.13
Restricted stock units vested		(7,561	)		44.08
Restricted stock units forfeited		(2,129	)		48.01
Outstanding as of December 31, 2025		262,184		$	36.66
Unvested and expected to vest as of December 31, 2025		262,184		$	36.66

During the years ended December 31, 2025 and 2024, the Company granted RSUs with a weighted-average grant date fair value of $36.13 and $44.62 per unit, respectively. The total fair value of RSUs vested during the year ended December 31, 2025 was $0.1 million. No RSUs vested during the year ended December 31, 2024.

Upon vesting of RSUs, the Company withholds shares with a fair value equal to the minimum statutory tax withholding requirements. During the year ended December 31, 2025, 859 shares were withheld for tax purposes. Shares withheld are accounted for as a reduction of additional paid-in capital within stockholders’ equity.

Stock-Based Compensation Expense

The following table is a summary of stock-based compensation expense recognized by function:


	Year Ended December 31,
	2025		2024
General and administrative	$	6,003	$	2,309
Research and development		4,494		1,182
Total stock-based compensation expense	$	10,497	$	3,491

The following table summarizes the unrecognized compensation expense and the weighted-average remaining period over which it is expected to be recognized, by type of award:


	As of December 31, 2025
	Unamortized Expense		Weighted Average Remaining Recognition Period (Years)
Stock options		21,445		2.5
RSUs		7,163		2.3

Modification of Certain Stock Options

In July 2024, the Company entered into a separation agreement with the Company’s Chief Operating Officer (the “Former Executive”). As part of the termination of employment, the Former Executive served as an advisor to the Company through March 31, 2025 (“Consulting Period”) on an as needed basis. Pursuant to the separation agreement, certain modifications to the Former Executive’s vested and non-vested stock option awards were executed including continued vesting of options during the Consulting Period and the extension of the post-termination exercise period of certain stock option awards. The services performed during the Consulting Period do not qualify as substantive services under ASC 718, Compensation—Stock Compensation; therefore, the continued vesting of these awards represents a modification to the original award. During the year ended December 31, 2024, the Company recorded the incremental stock-based compensation expense of $0.4 million for the modification of the stock options of the Former Executive. This amount is included in general and administrative expenses on the Consolidated Statement of Operations and Comprehensive Loss.

Income Taxes

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Abstract]

Income Taxes

13. INCOME TAXES

The components of net (loss) income before income tax expense are as follows:


	Year Ended December 31,
	2025			2024

Domestic	$	(73,150	)	$	(55,483	)
Foreign		229			(2,499	)
Loss before income tax	$	(72,921	)	$	(57,982	)

The components of the provision for income taxes are as follows:


	Year Ended December 31,
	2025			2024

Current expense (benefit):
Federal	$	—		$	—
State		45			—
Foreign		1,185			—
Total current expense (benefit):		1,230			—
Deferred expense (benefit):
Federal		14,931			13,004
State		4,127			3,181
Foreign		(380	)		741
Deferred tax benefit		18,678			16,926
Less change in valuation allowance		(18,678	)		(16,926	)
Total income tax expense (benefit)	$	1,230		$	—

The reconciliation of the Company's statutory tax rate and effective tax rate is as follows:


	Year Ended December 31,
	2025						2024
	Amount			Percent			Amount			Percent

Pretax loss	$	(72,921	)		-		$	(57,982	)		-

U.S. Federal statutory income tax rate		(15,313	)		21.0	%		(12,176	)		21.0	%
State and local income taxes, net of federal benefit(a)		45			(0.1	)%		-			—	%
Foreign tax effects:
Australia-tax on sale of commercialization rights		1,185			(1.6	)%		693			(1.2	)%
Australia-other		(37	)		0.1	%		-			—	%
Other foreign jurisdictions		(12	)		—	%		(168	)		0.3	%
Tax credits:
Federal R&D credit		(1,418	)		1.9	%		(1,247	)		2.2	%
Change in valuation allowance		14,931			(20.4	)%		13,004			(22.5	)%
Nontaxable or nondeductible items:
SAFE liability loss		-			—	%		968			(1.7	)%
Equity-based compensation		1,442			(2.0	)%		(727	)		1.3	%
Other		407			(0.6	)%		(347	)		0.6	%
Effective income tax rate	$	1,230			(1.7	)%	$	-			—	%

(a) State taxes in Massachusetts make up the majority (greater than 50 percent) of the tax effect in this category.

The components of the Company’s net deferred tax assets and liabilities are as follows:


	Year Ended December 31,
	2025			2024
Deferred tax assets
Net operating loss carryforward	$	123,867		$	109,392
Research credits		15,755			13,946
Accruals & other		913			863
Capitalized research and development expenses		43,829			40,742
Stock-based compensation		1,750			2,112
Amortization		3,167			3,555
Lease liability		240			660
Total deferred tax assets		189,521			171,270
Valuation allowance		(188,891	)		(170,177	)
Net deferred tax assets	$	630		$	1,093
Deferred tax liabilities
Depreciation	$	(394	)	$	(485	)
Right of use asset		(236	)		(608	)
Total deferred tax liabilities		(630	)		(1,093	)
Net deferred tax assets (liabilities)	$	—		$	—

As of December 31, 2025, the Company had $453.3 million of U.S. federal net operating loss carryforwards, all of which have an unlimited carryforward period. As of December 31, 2025, the Company had $123.7 million of state net operating loss carryforwards, which begin to expire at various dates from 2038 through 2045. As of December 31, 2025, the Company had $8.0 million of foreign net operating loss carryforwards, which is comprised of $7.6 million in Australia that have an unlimited carryforward period and $0.4 million in Canada that begin to expire in 2044.

As of December 31, 2025, the Company had $11.9 million of U.S. federal research and development tax credits that begin to expire in 2039. As of December 31, 2025, the Company had $4.9 million of state research and development tax credits that begin to expire at various dates from 2034 through 2040.

The future realization of the tax benefits from existing temporary differences and tax attributes ultimately depends on the existence of sufficient taxable income. The Company assesses the realizability of its deferred tax assets at each balance sheet date. In assessing the realization of its deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company considers the projected future taxable income, expected reversal of existing deferred tax liabilities, and tax planning strategies in making this assessment. After consideration of all available evidence, both positive and negative, the Company determined that it is not more likely than not that its net deferred tax assets will be realized in the foreseeable future. As a result, the Company increased its valuation allowance by $18.7 million as of December 31, 2025.

The future realization of the Company's net operating loss carryforwards and other tax attributes may also be limited by the change in ownership rules under the U.S. Internal Revenue Code Section 382. Under Section 382, if a corporation undergoes an ownership change (as defined), the corporation’s ability to utilize its net operating loss carryforwards and other tax attributes to offset income may be limited. The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes.

The Company does not provide for U.S. Federal, state, and applicable foreign income and withholding taxes on the financial reporting basis over the tax basis of its foreign subsidiary investment because the Company has the intentions and ability to indefinitely reinvest the undistributed earnings of its foreign subsidiaries. As a result, deferred taxes have not been recorded for the outside basis differences in its foreign subsidiary as of December 31, 2025 to the extent such differences are expected to result in future taxable income upon repatriation. The Company reviews its ability and intentions to indefinitely reinvest its foreign earnings at each balance sheet.

The Company records uncertain tax positions as liabilities in accordance with ASC 740-10 and adjusts these liabilities when judgment changes as a result of the evaluation of new information not previously available. Since there is complexity in some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. The calculation and assessment of the Company's income tax exposures generally involves the uncertainties in the application of complex tax laws and regulations for federal, state, and foreign jurisdictions. A tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon local tax examination including resolutions of any related appeals or litigation on the basis of the technical merits.

The Company files income tax returns in the US, Australia and Canada, which are the Company's major jurisdictions where it is subject to tax examination by local tax authorities. The Company is not currently under examination for income taxes, and is not aware of any issues

under review that could result in significant payments, accruals or material deviation from its tax positions. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by local tax authorities to the extent utilized in a future period. The statute of limitations for the Company has expired for tax years prior to 2021.

The following summarizes the Company's income taxes paid (net of refunds received) for the years presented :


	Year Ended December 31,
	2025		2024
Federal	$	—	$	—
State		45		—
Foreign		1,185		—
Total income tax paid, net	$	1,230	$	—

The following summarizes the jurisdictions that exceeded 5% of the Company's total income taxes paid (net of refunds) for the years presented:


	Year Ended December 31,
	2025		2024

Australia	$	1,185	*

* Jurisdiction below the threshold for the period presented.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Employee Benefit Plan

12 Months Ended

Dec. 31, 2025

Defined Contribution Plan [Abstract]

Employee Benefit Plan

15. EMPLOYEE BENEFIT PLAN

The Company has a 401(k) retirement plan (the “Plan”) that covers eligible U.S. employees. Eligible employees may elect to contribute up to the maximum limits, as set by the Internal Revenue Service, of their eligible compensation. The Company’s funding policy is to contribute 3% (“Nonelective Contribution”) of employees’ eligible pay to the Plan. The Company recognized compensation expense related to the Plan of $0.4 million and $0.2 million for the years ended December 31, 2025 and 2024, respectively.

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Payables and Accruals [Abstract]
Accrued compensation and related expenses	$ 4,110	$ 3,585
Accrued research and development expenses	2,301	2,787
Accrued other expenses	929	1,478
Total accrued expenses and other current liabilities	$ 7,340	$ 7,850

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Income Taxes [Line Items]
Deferred income tax expense benefit	$ 18,678	$ 16,926
Effective income tax rate continuing operations	(1.70%)	0.00%
Federal Current Expenses	$ 0	$ 0
State Current Expense	45	0
Income tax expense	1,230	0
Valuation allowance deferred tax asset change in amount	18,700
Net operating loss carryforward	123,867	109,392
Deferred tax assets operating loss carryforwards domestic	453,300
Deferred tax assets operating loss carryforwards state and local	123,700
Foreign Net Operating loss Carryforwards	8,000
Federal R&D credit amount	(1,418)	(1,247)
valuation allowance	630	$ 1,093
Australia
Income Taxes [Line Items]
Foreign Net Operating loss Carryforwards	7,600
CANADA
Income Taxes [Line Items]
Foreign Net Operating loss Carryforwards	400
U.S
Income Taxes [Line Items]
Federal R&D credit amount	11,900
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Federal R&D credit amount	$ 4,900

Equity Incentive Plans - Summary Of Unrecognized Compensation Expense And Weighted-Average Remaining Period (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Unrecognized Compensation Expense And Weighted Average Remaining Period [Line Item]
Unamortized Expense	$ 10,497	$ 3,491
Restricted Stock Units [Member]
Unrecognized Compensation Expense And Weighted Average Remaining Period [Line Item]
Unamortized Expense	$ 7,163
Weighted average remaining recognition period (Years)	2 years 3 months 18 days
Stock Options [Member]
Unrecognized Compensation Expense And Weighted Average Remaining Period [Line Item]
Unamortized Expense	$ 21,445
Weighted average remaining recognition period (Years)	2 years 6 months

INCOME TAXES - Schedule of Deferred tax assets and liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Net operating loss carryforward	$ 123,867	$ 109,392
Research credits	15,755	13,946
Lease liability	240	660
Capitalized research and development expenses	43,829	40,742
Accruals and other	913	863
Amortization	3,167	3,555
Stock-based compensation	1,750	2,112
Deferred Tax Assets, Gross, Total	189,521	171,270
Valuation allowance	(188,891)	(170,177)
Deferred Tax Assets, Net of Valuation Allowance, Total	630	1,093
Depreciation	(394)	(485)
Right of use asset	(236)	(608)
Total deferred tax liabilities	(630)	(1,093)
Deferred Tax Assets, Net, Total	$ 0	$ 0

Equity Incentive Plans - Summary of the Stock Option Activity (Detail) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2025 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding as of January 1, 2025 \| shares	92,480
Options Exercised, Number of Shares \| shares	(71,215)
Options Forfeited and expired, Number of Shares \| shares	(21,265)
Outstanding as of December 31, 2025 \| shares	0
Options vested and exercisable as of December 31, 2025 \| shares	0
Options vested and expected to vest as of December 31, 2025 \| shares	0
Opening Balance, Weighted- Average Exercise Price \| $ / shares	$ 22.69
Options Exercised, Weighted- Average Exercise Price \| $ / shares	12.61
Options Forfeited and expired, Weighted- Average Exercise Price \| $ / shares	56.44
Closing Balance, Weighted- Average Exercise Price \| $ / shares	0
Options vested and exercisable, Weighted- Average Exercise Price \| $ / shares	0
Options vested and expected to vest, Weighted- Average Exercise Price \| $ / shares	$ 0
Options Exercised, Aggregate Intrinsic Value \| $	$ 2,099
Ending Balance, Aggregate Intrinsic Value \| $	0
Options vested and exercisable, Aggregate Intrinsic Value \| $	0
Aggregate Intrinsic Value, Unvested and expected to vest as of December 31, 2025 \| $	$ 0
2019 and 2024 Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding as of January 1, 2025 \| shares	1,534,361
Options Granted, Number of Shares \| shares	559,873
Options Exercised, Number of Shares \| shares	(114,558)
Options Forfeited and expired, Number of Shares \| shares	(28,259)
Outstanding as of December 31, 2025 \| shares	1,951,417
Options vested and exercisable as of December 31, 2025 \| shares	792,535
Options vested and expected to vest as of December 31, 2025 \| shares	1,951,417
Opening Balance, Weighted- Average Exercise Price \| $ / shares	$ 12.49
Options Granted, Weighted- Average Exercise Price \| $ / shares	35.21
Options Exercised, Weighted- Average Exercise Price \| $ / shares	2.91
Options Forfeited and expired, Weighted- Average Exercise Price \| $ / shares	14.27
Closing Balance, Weighted- Average Exercise Price \| $ / shares	19.55
Options vested and exercisable, Weighted- Average Exercise Price \| $ / shares	13.45
Options vested and expected to vest, Weighted- Average Exercise Price \| $ / shares	$ 19.55
Weighted-Average Remaining Contractual Term (Years)	8 years 2 months 12 days
Options vested and exercisable, Weighted-Average Remaining Contractual Term (Years)	7 years 6 months
Weighted-Average Remaining Contractual Term (Years) Unvested and expected to vest as of December 31, 2025	8 years 2 months 12 days
Options Exercised, Aggregate Intrinsic Value \| $	$ 3,240
Ending Balance, Aggregate Intrinsic Value \| $	12,532
Options vested and exercisable, Aggregate Intrinsic Value \| $	8,004
Aggregate Intrinsic Value, Unvested and expected to vest as of December 31, 2025 \| $	$ 12,532

Segment Information (Tables)

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Schedule of segment net loss and significant segment expenses

The following table presents the segment net loss and significant segment expenses for the years ended December 31, 2025 and 2024:


	Year Ended December 31,
	2025		2024
Employee-related expenses:
Research and development employee-related expenses	$	12,961	$	11,135
General and administrative employee-related expenses		5,548		5,553

External research and development expenses:
Research and preclinical expenses		7,001		8,477
Clinical and development expenses		23,798		15,380
Chemistry, manufacturing, and control expenses		10,052		3,570
Non-clinical science expenses		3,667		—

Non-employee-related general and administrative expenses		8,985		8,733
Other segment items1		2,139		5,134
Net loss	$	74,151	$	57,982

License agreements (Additional Information) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research And Development Expense	$ 63,489	$ 41,364
Harvard Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License Agreements Payments Description	(1) annual maintenance fees ranging from the low five digits to the low six digits during the term of the License Agreement (through the first commercial sale of a royalty-bearing product); (2) milestone payments payable upon regulatory approval and the achievement of specified clinical and commercial milestones for licensed products or know-how enabled products; (3) royalty payments as a percentage in the low single digits of the annual net sales that the Company generates from products that utilize the license technology (“Licensed Products”) and royalty payments as a percentage in the low single digits of the annual net sales that the Company generates from know-how enabled product licenses (“Know-How Enabled Products”) and (4) a percentage between 10-20% of all non-royalty income received by the Company under sublicenses, strategic partnerships and know-how enabled product licenses that utilize the license technology.
Research And Development Expense	$ 100	400
License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research And Development Expense	100	400
Amount Due to Related Party	$ 0	$ 0

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 253,798	$ 141,239
Prepaid expenses and other current assets	2,974	5,618
Restricted cash	587	0
Total current assets	257,359	146,857
Property and equipment, net	1,185	2,151
Finance right-of-use assets, net	495	919
Operating right-of-use assets	874	2,235
Restricted cash	485	587
Other assets	640	156
Total assets	261,038	152,905
Current liabilities:
Accounts payable	1,093	976
Accrued expenses and other current liabilities	7,340	7,850
Operating lease liability	889	2,295
Finance lease liability	344	489
Total current liabilities	9,666	11,610
Operating lease liability, non-current	0	132
Finance lease liability, non-current	43	387
Total liabilities	9,709	12,129
Commitments and contingencies (Note 10)
Stockholders' Equity (Deficit):
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024; no shares issued and outstanding as of December 31, 2025 and December 31, 2024	0	0
Common stock, $0.0001 par value; 150,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 18,713,223 and 14,856,309 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	2	2
Additional paid-in capital	474,160	289,351
Accumulated other comprehensive (loss) income	(96)	9
Accumulated deficit	(222,737)	(148,586)
Total stockholders' equity	251,329	140,776
Total liabilities and stockholders' equity	$ 261,038	$ 152,905

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2025

Table Text Block [Abstract]

Reconciliation of Cash, Cash Equivalents and Restricted Cash


	December 31,
	2025		2024
Cash and cash equivalents	$	253,798	$	141,239
Restricted cash		1,072		587
Cash, cash equivalents and restricted cash		254,870		141,826

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Dec. 31, 2025 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	Item 9B. Other Information. During the three months ended December 31, 2025, the following directors of the Company adopted a “Rule 10b5-1 trading arrangement” as the term is defined in Item 408(a) of Regulation S-K, all of which were entered into during an open trading window in accordance with the Company’s Insider Trading Policy and all of which were intended to satisfy Rule 10b5-1(c): • On November 14, 2025, Peter McNamara, a member of our Board of Directors, adopted a Rule 10b5-1 trading plan that provides for the sale of up to 35,102 shares of common stock from the exercise of vested stock options. The plan will expire on December 14, 2026 subject to early termination for specified events set forth in the plan. Except as set forth above, no director or officer of the Company adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K during the three months ended December 31, 2025.
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Non-Rule10b5-1 Arrangement Modified [Flag]	false
Rule10b5-1 Arrangement Modified [Flag]	false
Peter McNamara [Member]
Trading Arrangements, by Individual
Name	Peter McNamara
Title	Board of Directors
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	November 14, 2025
Expiration Date	December 14, 2026
Aggregate Available	35,102

Segment Information (Additional Information) (Details)	12 Months Ended
Segment Information (Additional Information) (Details)	Dec. 31, 2025 Segment
Segment Reporting [Abstract]
Number of operating segments	1
Number of reportable segments	1

Net Loss Per Share

12 Months Ended

Dec. 31, 2025

Earnings Per Share [Abstract]

Net Loss Per Share

9. Net loss per share

The following table summarizes the computation of basic and diluted net loss per share:


	Year Ended December 31,
	2025			2024
Numerator:
Net loss	$	(74,151	)	$	(57,982	)
Denominator:
Weighted-average common shares outstanding, basic and diluted		18,322,533			8,490,171
Net loss per share, basic and diluted	$	(4.05	)	$	(6.83	)

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:


	As of December 31,
	2025		2024
Options to purchase common stock		1,951,417		1,626,841
Unvested restricted stock units		262,184		25,612
Total		2,213,601		1,652,453

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Abstract]

Schedule Of Net (loss) Income Before Income Tax Expense

The components of net (loss) income before income tax expense are as follows:


	Year Ended December 31,
	2025			2024

Domestic	$	(73,150	)	$	(55,483	)
Foreign		229			(2,499	)
Loss before income tax	$	(72,921	)	$	(57,982	)

ScheduleOfComponentsOfIncomeTaxExpenseBenefit


	Year Ended December 31,
	2025			2024

Current expense (benefit):
Federal	$	—		$	—
State		45			—
Foreign		1,185			—
Total current expense (benefit):		1,230			—
Deferred expense (benefit):
Federal		14,931			13,004
State		4,127			3,181
Foreign		(380	)		741
Deferred tax benefit		18,678			16,926
Less change in valuation allowance		(18,678	)		(16,926	)
Total income tax expense (benefit)	$	1,230		$	—

ScheduleOfEffectiveIncomeTaxRateReconciliation


	Year Ended December 31,
	2025						2024
	Amount			Percent			Amount			Percent

Pretax loss	$	(72,921	)		-		$	(57,982	)		-

U.S. Federal statutory income tax rate		(15,313	)		21.0	%		(12,176	)		21.0	%
State and local income taxes, net of federal benefit(a)		45			(0.1	)%		-			—	%
Foreign tax effects:
Australia-tax on sale of commercialization rights		1,185			(1.6	)%		693			(1.2	)%
Australia-other		(37	)		0.1	%		-			—	%
Other foreign jurisdictions		(12	)		—	%		(168	)		0.3	%
Tax credits:
Federal R&D credit		(1,418	)		1.9	%		(1,247	)		2.2	%
Change in valuation allowance		14,931			(20.4	)%		13,004			(22.5	)%
Nontaxable or nondeductible items:
SAFE liability loss		-			—	%		968			(1.7	)%
Equity-based compensation		1,442			(2.0	)%		(727	)		1.3	%
Other		407			(0.6	)%		(347	)		0.6	%
Effective income tax rate	$	1,230			(1.7	)%	$	-			—	%

ScheduleOfDeferredTaxAssetsAndLiabilities

The components of the Company’s net deferred tax assets and liabilities are as follows:


	Year Ended December 31,
	2025			2024
Deferred tax assets
Net operating loss carryforward	$	123,867		$	109,392
Research credits		15,755			13,946
Accruals & other		913			863
Capitalized research and development expenses		43,829			40,742
Stock-based compensation		1,750			2,112
Amortization		3,167			3,555
Lease liability		240			660
Total deferred tax assets		189,521			171,270
Valuation allowance		(188,891	)		(170,177	)
Net deferred tax assets	$	630		$	1,093
Deferred tax liabilities
Depreciation	$	(394	)	$	(485	)
Right of use asset		(236	)		(608	)
Total deferred tax liabilities		(630	)		(1,093	)
Net deferred tax assets (liabilities)	$	—		$	—

Schedule of Net Income Taxes Paid of Refund Received

The following summarizes the Company's income taxes paid (net of refunds received) for the years presented :


	Year Ended December 31,
	2025		2024
Federal	$	—	$	—
State		45		—
Foreign		1,185		—
Total income tax paid, net	$	1,230	$	—

The following summarizes the jurisdictions that exceeded 5% of the Company's total income taxes paid (net of refunds) for the years presented:


	Year Ended December 31,
	2025		2024

Australia	$	1,185	*

* Jurisdiction below the threshold for the period presented.

Leases - Additional Information (Detail) $ in Thousands		1 Months Ended
Leases - Additional Information (Detail) $ in Thousands	Sep. 30, 2025 USD ($)	Nov. 30, 2020 ft²	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)
Lessee, Lease, Description [Line Items]
Future Minimum Lease Payments	$ 5,300
Operating right-of-use assets			$ 874	$ 2,235
Operating Lease for Office and Laboratory Spaces [Member]
Lessee, Lease, Description [Line Items]
Area of real estate \| ft²		19,000
Operating lease date of expiry		Jan. 31, 2026
Operating right-of-use assets			$ 800
Operating lease date of expiry revised		Apr. 21, 2022

Accrued Expenses and Other Current Liabilities (Tables)

12 Months Ended

Dec. 31, 2025

Payables and Accruals [Abstract]

Summary of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities is comprised of the following:


	December 31, 2025		December 31, 2024
Accrued compensation and related expenses	$	4,110	$	3,585
Accrued research and development expenses		2,301		2,787
Accrued other expenses		929		1,478
Total accrued expenses and other current liabilities	$	7,340	$	7,850

Merger

12 Months Ended

Dec. 31, 2025

Merger [Abstract]

Merger

3. Merger

As described in Note 1, Nature of the Business, the Company completed its Merger with AVROBIO on June 20, 2024. The Merger was accounted for as a reverse recapitalization in accordance with GAAP, with Legacy Tectonic as the accounting acquirer of AVROBIO. At the effective time of the Merger, substantially all the assets of AVROBIO consisted of cash and cash equivalents, as well as other nominal assets. Under such reverse recapitalization accounting, the assets and liabilities of AVROBIO were recorded at their fair value at the effective time of the Merger, which approximated book value due to the short-term nature. No goodwill or intangible assets were recognized. Consequently, the consolidated financial statements of the Company reflect the historical operations of Legacy Tectonic for accounting purposes together with the issuance of shares to the former shareholders of AVROBIO, the legal acquirer, and a recapitalization of the equity of Legacy Tectonic, the accounting acquirer. The exchange ratio was retroactively applied to all outstanding common shares, convertible preferred shares, stock options and restricted stock of Legacy Tectonic.

As part of the recapitalization, Legacy Tectonic recognized the assets and liabilities listed below:


Cash and cash equivalents	$	85,230
Prepaid expenses and other current assets		319
Accounts payable		(1,988	)
Accrued expenses and other current liabilities		(5,405	)
Net assets acquired	$	78,156

The Company incurred transaction costs of $9.3 million which was recorded as a reduction to additional paid-in capital in the Consolidated Balance Sheet for the year ended December 31, 2024.

Equity Incentive Plans - Summary of Fair Values of the Options Granted (Detail)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Expected volatility ,Minimum	102.60%	100.00%
Expected volatility ,Maximum	103.70%	104.00%
Expected dividend yield	0.00%	0.00%
Maximum [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Expected term (in years)	6 years 3 months	6 years 3 months
Risk-free interest rate	4.43%	4.26%
Minimum [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Expected term (in years)	5 years 6 months	6 years
Risk-free interest rate	3.76%	4.10%

Fair Value Measurements - (Additional Information) (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2025	Dec. 31, 2024	Jun. 20, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Proceeds from the issuance of SAFEs	$ 34,100
Common stock, shares, issued		18,738,249	14,856,309
Common stock, price per share		$ 0.0001	$ 0.0001
Fair value input amount transfer in between levels		$ 0	$ 0
Simple Agreements for Future Equity [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock, shares, issued		2,752,216		2,752,216
Common stock, price per share		$ 12.4		$ 12.4
Simple Agreements for Future Equity [Member] \| AVROBIO
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Common stock, shares, issued		1,470,839
Common stock, price per share		$ 12.4

Net Loss Per Share - Summary of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Net Income (Loss) Attributable to Parent [Abstract]
Net loss, basic	$ (74,151)	$ (57,982)
Net loss, diluted	$ (74,151)	$ (57,982)
Weighted-average common shares outstanding, basic	18,322,533	8,490,171
Weighted-average common shares outstanding, diluted	18,322,533	8,490,171
Net loss per share, basic	$ (4.05)	$ (6.83)
Net loss per share, diluted	$ (4.05)	$ (6.83)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

+ Details

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

+ Details

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.

+ References + Details

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Operating expenses:
Research and development	$ 63,489	$ 41,364
General and administrative	20,547	16,651
Total operating expenses	84,036	58,015
Loss from operations	(84,036)	(58,015)
Other income (expense):
Interest income	11,297	4,261
Interest expense	(63)	(107)
Change in fair value of SAFE liabilities	0	(3,610)
Other expense	(119)	(511)
Total other income, net	11,115	33
Loss before income tax	(72,921)	(57,982)
Income tax expense	(1,230)	0
Net loss	(74,151)	(57,982)
Other comprehensive loss:
Foreign currency translation adjustment	(105)	9
Comprehensive loss	$ (74,256)	$ (57,973)
Net loss per share, basic	$ (4.05)	$ (6.83)
Net loss per share, diluted	$ (4.05)	$ (6.83)
Weighted-average common shares outstanding, basic	18,322,533	8,490,171
Weighted-average common shares outstanding, diluted	18,322,533	8,490,171

Equity Incentive Plans - Summary of Restricted Stock Units (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2025 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options vested and expected to vest as of December 31, 2025	0
Aggregate Intrinsic Value, Unvested and expected to vest as of December 31, 2025 \| $	$ 0
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unvested restricted stock awards as of January 1, 2024	25,612
Restricted stock units granted	246,262
Vested	(7,561)
Restricted stock units forfeited	(2,129)
Unvested restricted stock awards as of December 31, 2024	262,184
Options vested and expected to vest as of December 31, 2025	262,184
Weighted Average Grant Date Fair Value, Outstanding as of January 1, 2025 \| $ / shares	$ 44.9
Weighted Average Grant Date Fair Value, Restricted stock units granted \| $ / shares	36.13
Weighted Average Grant Date Fair Value per Unit Vested \| $ / shares	44.08
Weighted Average Grant Date Fair Value, Restricted stock units forfeited \| $ / shares	48.01
Weighted Average Grant Date Fair Value, Outstanding as of December 31, 2025 \| $ / shares	36.66
Weighted Average Grant Date Fair Value, Unvested and expected to vest as of December 31, 2025 \| $ / shares	$ 36.66

Merger - Summary Of The Company Obtain The Assets And Liabilities (Detail) $ in Thousands	Dec. 31, 2025 USD ($)
Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) [Abstract]
Cash and cash equivalents	$ 85,230
Prepaid expenses and other current assets	319
Accounts payable	(1,988)
Accrued expenses and other current liabilities	(5,405)
Net assets acquired	$ 78,156

Summary of Significant Accounting Policies and Basis of Presentation - (Additional Information) (Details) $ in Thousands		12 Months Ended
	Jun. 20, 2024	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)
Property, Plant and Equipment [Line Items]
Stock split, conversion ratio	0.53
Impairment		$ 0	$ 0

Commitments and Contingencies - (Additional Information) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Other Commitments [Line Items]
Accounts payable and accrued liabilities, current	$ 7,340	$ 7,850
AVROBIO, Inc. [Member]
Other Commitments [Line Items]
Period after closing with which assets may be disposed to pay the amount as per agreement	18 months

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2025

Earnings Per Share [Abstract]

Summary of Basic and Diluted Earnings Per Share

The following table summarizes the computation of basic and diluted net loss per share:


	Year Ended December 31,
	2025			2024
Numerator:
Net loss	$	(74,151	)	$	(57,982	)
Denominator:
Weighted-average common shares outstanding, basic and diluted		18,322,533			8,490,171
Net loss per share, basic and diluted	$	(4.05	)	$	(6.83	)

Summary of Diluted Net Loss Per Share Attributable to Common Stockholders


	As of December 31,
	2025		2024
Options to purchase common stock		1,951,417		1,626,841
Unvested restricted stock units		262,184		25,612
Total		2,213,601		1,652,453

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

Basis of Presentation

Principles of Consolidation

The Company consolidates the financial statements of its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Reverse Stock Split and Exchange Ratio

Use of Estimates

Foreign Currency

Segment Information

Cash, Cash Equivalents, Restricted Cash, and Concentration of Credit Risk


	December 31,
	2025		2024
Cash and cash equivalents	$	253,798	$	141,239
Restricted cash		1,072		587
Cash, cash equivalents and restricted cash		254,870		141,826

Property and Equipment

Long-Lived Assets

No impairment losses were recognized during the years ended December 31, 2025 and 2024.

Fair Value Measurements

A three-level fair value hierarchy has been established to prioritize the inputs used in measuring fair value as follows:

Level 1 — Quoted prices in active markets for identical assets or liabilities.

Level 3 — Valuations that require inputs that are both significant to the fair value measurement and unobservable.

Financial instruments are classified in their entirety within the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

Research and Development Expenses

Leases

Refer to Note 10, Leases, for additional information.

Stock-Based Compensation Valuation and Expense

•

Expected Dividend—The expected dividend yield is assumed to be zero as the Company has not declared or paid dividends to date and does not anticipate declaring dividends for the foreseeable future.

Income Taxes

Net Loss per Share

Comprehensive Loss

Recent Accounting Pronouncements

Recently Adopted Accounting Standards

Recently Issued Accounting Pronouncements Not Yet Adopted

Recently Issued Accounting Standards Not Yet Adopted

Employee Benefit Plan - Additional Information (Detail) - Retirement Plan Name, Other [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Defined Contribution Plan Disclosure [Line Items]
Defined contribution plan employee mathing contribution percentage	3.00%
Contribution by company	$ 0.4	$ 0.2

- Definition

Amount of contribution received by defined benefit plan from employer which increases plan assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480482/715-20-55-17

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480482/715-20-55-18

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

+ Details

Equity Incentive Plans - Summary of Restricted Stock Activity (Detail) - Restricted Common Stock [Member]	12 Months Ended
	Dec. 31, 2025 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unvested restricted stock awards as of January 1, 2024	25,612
Restricted stock units granted	246,262
Vested	(7,561)
Restricted stock units forfeited	2,129
Unvested restricted stock awards as of December 31, 2024	262,184

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Related Party Transactions

12 Months Ended

Dec. 31, 2025

Related Party Transactions

14. RELATED PARTY TRANSACTIONS

The Company enters into transactions with related parties in the ordinary course of business. Related parties include the Company’s directors, executive officers, principal stockholders, and entities in which such individuals have a controlling financial interest.

Scientific Advisory Board Member

One of the Company’s co-founders and former director is a member of the Company’s Scientific Advisory Board and meets the criteria of a related party. For each of the years ended December 31, 2025 and 2024, the Company incurred expense of $0.1 million for advisory services provided. There were no amounts due to this related party as of December 31, 2025 or 2024.

License Agreement

Harvard meets the criteria of a related party resulting from the Company’s co-founders’ employment as professors in the Harvard Department of Molecular Pharmacology. Core intellectual property utilized by the Company is licensed from Harvard under the License Agreement described in Note 11, License Agreements.

The Company incurred expense of $0.1 million and $0.4 million related to the License Agreement during the years ended December 31, 2025 and 2024, respectively. No amounts were due to Harvard related to the License Agreement as of December 31, 2025 and 2024.

Private Placement

The Company issued shares in connection with the Private Placement at a price of $54.14 per share to accredited investors that are either an officer or director of the Company.

SAFE Agreements

From October through December 2023, Legacy Tectonic entered into multiple SAFE agreements with certain existing investors and received proceeds of $34.1 million. All investors were considered related parties of the Company. The SAFE agreements had no maturity date, bore no interest, and were redeemable by Legacy Tectonic upon the occurrence of a triggering event, including the Merger which qualified as a public listing transaction under the SAFE agreements. The SAFEs were redeemed for shares of Legacy Tectonic common stock in connection with the closing of the Merger. As of December 31, 2024, no related-party SAFEs were outstanding, and the Company had no further obligations under these agreements.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

+ Details

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (unaudited) (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2025 USD ($)
Transaction Costs	$ 9,300
Common Stock [Member]
Transaction Costs	9,300
At the Market Facility [Member]
Net of offering costs	2,000
Private Placement [Member]
Net of offering costs	$ 11,928

Leases - Schedule of Future Commitments Due Under These Lease Agreements (Detail) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Leases [Abstract]
2026	$ 948
2027	0
Thereafter	0
Total undiscounted cash flows	948
Less: interest	(59)
Total lease liabilities	889
Operating lease liability	889	$ 2,295
Operating lease liability Non-current	0	132
2026	363
2027	44
Thereafter	0
Total lease payments	407
Less: interest	(20)
Total lease liabilities	387
Finance lease liability	344	489
Finance Lease Liability Non-current	43	$ 387
2026	1,311
2027	44
Thereafter	0
Total undiscounted cash flows	1,355
Less: interest	79
Total lease liabilities	1,276
Lease Liability Current	(1,233)
Lease Liability Noncurrent	$ 43

Property and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2025

Property, Plant and Equipment [Abstract]

Summary of Property and Equipment Net

Property and equipment, net is comprised of the following:


	December 31, 2025			December 31, 2024
Laboratory equipment	$	4,286		$	4,590
Office equipment, furniture and fixtures		281			281
Leasehold improvements		25			25
		4,592			4,896
Less: accumulated depreciation		(3,407	)		(2,745	)
Property and equipment, net	$	1,185		$	2,151

Equity Incentive Plans - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Unexercised or outstanding stock options	$ 0
Proceeds from the exercise of stock options	$ 1,231	$ 1,624
Common stock, capital shares reserved for future issuance	3,434,874	2,775,878
Stock Compensation Expense		$ 400
Restricted Stock Units [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation by share based award equity instruments other than options non vested	262,184	25,612
Options Granted, Weighted-average grant-date fair value	$ 36.13	$ 44.62
Shares were withheld for tax purposes	859
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value	$ 100	$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value	$ 100	$ 0
Common stock, capital shares reserved for future issuance	262,184	25,612
2024 Equity Incentive Plan [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Common stock, capital shares reserved for future issuance	936,912
Common stock capital shares reserved for future issuance term description	The number of shares of common stock available for issuance under the 2024 Plan will automatically increase on January 1st of each year through January 1, 2034, in an amount equal to the lesser of (a) 5% of the total number of shares of common stock issued and outstanding determined as of the day prior to such increase, or (b) an amount determined by the Board of Directors. On January 1, 2026, the number of shares of common stock available for issuance under the 2024 Plan automatically increased by 936,912 shares.
2024 Employee Stock Purchase Plan [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Common stock, capital shares reserved for future issuance	187,382
Common stock capital shares reserved for future issuance term description	2034, in an amount equal to the lesser of (a) 1% of the total number of shares of common stock issued and outstanding determined as of the day prior to such increase, (b) a number of shares qual to three times the initial share reserve , or (c) an amount determined by the Board of Directors
2019 and 2024 Employee Stock Purchase Plan [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Options Granted, Weighted-average grant-date fair value	$ 29.04	$ 14.9
Aggregate intrinsic value of options exercised	$ 3,200	$ 5,600
Unexercised or outstanding stock options	$ 12,532

Cover Page - USD ($) $ in Millions	12 Months Ended
Cover Page - USD ($) $ in Millions	Dec. 31, 2025	Feb. 16, 2026	Jun. 30, 2025
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2025
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	FY
Entity Registrant Name	TECTONIC THERAPEUTIC, INC.
Entity Central Index Key	0001681087
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Public Float			$ 232.0
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity File Number	001-38537
Entity Tax Identification Number	81-0710585
Entity Address, Address Line One	490 Arsenal Way
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Watertown
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02472
City Area Code	339
Local Phone Number	666-3320
Entity Incorporation, State or Country Code	DE
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	TECX
Security Exchange Name	NASDAQ
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Documents Incorporated by Reference	Portions of the registrant’s definitive Proxy Statement relating to the 2026 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2025.
Auditor Firm ID	34
Auditor Location	Boston, Massachusetts
Auditor Name	Deloitte & Touche LLP
Auditor Opinion	Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Tectonic Therapeutic, Inc. and subsidiaries (the "Company") as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders' equity (deficit), and cash flows for the years then ended⁠, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.
Entity Common Stock, Shares Outstanding		18,776,626

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Pay vs Performance Disclosure
Net Income (Loss)	$ (74,151)	$ (57,982)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2025

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

12. COMMITMENTS AND CONTINGENCIES

Commitments

The Company enters into contractual agreements with various suppliers in the normal course of its business. All contracts are terminable, with varying provisions regarding termination. If a contract with a specific vendor were to be terminated, the Company would only be obligated for the products or services that the Company had received through the time of termination.

The Company is also party to lease commitments, as described in Note 10, Leases, and milestone, royalty and maintenance based commitments, as described in Note 11, License Agreements.

Contingencies

In connection with the Merger, the Company and its designated rights agent entered into a contingent value rights agreement (the “CVR Agreement”). Pursuant to the CVR Agreement, each holder of AVROBIO common stock immediately prior to the closing received a contractual contingent value right (“CVR”) representing the contractual right to receive a pro rata portion of any net proceeds, if any, resulting from the disposition of certain AVROBIO intellectual property after the closing, subject to the terms of the CVR Agreement. The CVR Agreement expired 18 months following the closing of the Merger and is no longer in effect. No AVROBIO intellectual property was sold or otherwise disposed of, and, as a result, no payments were made or are due under the agreement. The Company did not record any receivables or liabilities related to the CVRs on the Consolidated Balance Sheets as of December 31, 2025 and 2024.

From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. There are no matters pending that the Company currently believes are reasonably possible or probable of having a material impact to the Company's financial position, results of operations, or statements of cash flows.

In the normal course of operations, the Company may become involved in various legal proceedings. As of December 31, 2025 and 2024, the Company has not recorded accruals for probable losses related to any existing or pending litigation as the Company’s management has determined that there are no matters where a potential loss is probable and reasonably estimable. The Company does not believe that any existing or pending claims would have a material impact on the Company’s consolidated financial statements.